NEW YORK (GenomeWeb) – MRM and Biodesix said today that they are partnering to develop mass spectrometry-based assays for lung cancer.

Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI technologies to develop blood-based tests for lung cancer.

MRM's iMALDI method uses upfront enrichment of target proteins followed by MALDI mass spec analysis of those proteins.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.